VALIDATE-BSI 2019 Conference Programme

Wednesday 2 October 2019 (afternoon and evening)

1200 Registration and buffet lunch for all delegates

1300 Welcome

1300 Prof Helen McShane

VALIDATE Director, University of Oxford, UK

Welcome to conference & introduction to VALIDATE

1310 Dr Doug Brown

Chief Executive, British Society for Immunology (BSI), UK

BSI Welcome address

1320 Session 1: Tissue-specific immunity, host-pathogen interactions, macrophages and the microenvironment - Chair Prof Andrea Cooper, University of Leicester

1320 Keynote Speaker: Prof Clare Lloyd

Imperial College London, UK

Local and environmental cues dictate the nature of the pulmonary immune response (abstract)

1400 Dr Barbara Kronsteiner-Dobramysl

University of Oxford, UK

Diabetes alters cellular metabolism of T cells: implications for vaccine development (abstract)

1420 Dr Chidchamai Kewcharoenwong

Khon Kaen University, Thailand

Glibenclamide alters cytokine production of primary human monocytes from diabetic individuals against Mycobacterium tuberculosis infection (abstract)

1440 Dr Isadora Lima

FIOCRUZ, Brazil

Canine visceral leishmaniasis: the role of tissue-specific immunity in the progression of disease (abstract)

1500 Tea/coffee break

1530 Keynote Speaker: Prof Tracy Hussell

University of Manchester, UK

Innate sensing of lung health and disease (abstract)

1610 Dr Lisa Stockdale

University of Oxford, UK

Cytomegalovirus as a correlate of risk for TB? (abstract)

1630 Poster turbo talks:

1630 Asst Prof Kiran Afshan, Quaid-i-Azam University, Pakistan

Cutaneous Leishmaniasis in Khyber Pakhtunkhwa, Pakistan (abstract)

1634 Dr Anthony Afum-Adjei Awuah, Kumasi Centre for Collaborative Research (KCCR), Ghana

Why fix when you can prevent; towards TB Vaccines Research in Ghana (abstract)

1638 Dr Federico Carlos Blanco, National Institute of Agricultural Technology (INTA), Argentina

The isolate Mb04-303 induce a proinflammatory innate immune profile and is a potential candidate for an attenuated mutant vaccine against bovine tuberculosis (abstract)

1642 Assoc Prof Mary Burtnick, University of Nevada, Reno, USA

Optimization of melioidosis subunit vaccines using Burkholderia thailandensis E555 (abstract)

1646 Dr Panjaporn Chaichana, MORU, Thailand

Identification of protective antibody profiles for vaccine development against melioidosis (abstract)

1650 Assoc Prof Narisara Chantratita, Mahidol University, Thailand

Risk of Burkholderia pseudomallei infection, host immune response and biomarkers for melioidosis (abstract)

1654 Asst Prof Ganjana Lertmemongkolchai, Khon Kaen University, Thailand

Metformin-induced suppression of IFN-α expression via mTORC1 signalling following seasonal vaccination is associated with impaired antibody responses in diabetes mellitus (abstract)

1658 Dr Rachel Okojie, University of Benin, Nigeria

Comparative study of the immunological and haematological parameters among tuberculosis naive and treated patients in Central Hospital, Benin City, Nigeria (abstract)

1702 Dr Olayinka Osuolale, Elizade University, Nigeria

Leishmaniasis in patients attending a medical health center in the rural community of Ilara-Mokin, Ondo State, Nigeria (abstract)

1706 Asst Prof Vijay Kumar Prajapati, Central University of Rajasthan, India

Evaluation of immunogenicity of the engineered multi-epitope subunit vaccine against visceral leishmaniasis infection (abstract)

1710 Dr Lok Bahadur Shrestha, BP Koirala Institute of Health Sciences, Nepal

Emerging Clinical Microbiologist looking for research opportunity in TB Vaccinology (abstract)

1714 Dr Suwarti, Eijkman Oxford Clinical Research Unit (EOCRU), Indonesia

Intranasal boosting regimen of Human Parainfluenza Virus Type 2-Ag85B vaccines induces superior CD4 immune response against Mycobacterium tuberculosis (abstract)

1718 Dr Julen Tomás Cortázar, University College Dublin, Ireland

Elucidating the mechanisms of protection of the Burkholderia pseudomallei antigen, BpOmpW (abstract)

1722 Chathika Weersuriya, LSHTM, UK

Mathematical modelling of the epidemiological impact, cost-effectiveness and budget impact of novel tuberculosis vaccines on multi-drug resistant tuberculosis (abstract)

1730 Group photograph

Drinks reception with poster session (abstracts)

1900 Conference Dinner

Thursday 3 October 2019 (full day)

0830 Coffee/tea

0900 Session 2: Biomarkers - Chair Prof Helen Fletcher, LSHTM

0900 Keynote Speaker: Dr January Weiner

Berlin Institute of Health, Germany

Biomarkers in tuberculosis and individual variability of the host (abstract)

0940 Dr Fatoumatta Darboe

MRC Unit at LSHTM, The Gambia

Predicting and diagnosing TB disease in HIV-infected persons (abstract)

1000 Dr Eduardo Milton Ramos Sanchez

University of São Paulo, Brazil

Altered expression of microRNAs in infections with cutaneous and visceral strains of Leishmania (abstract)

1020 Tea/coffee break

1050 Keynote Speaker: Prof Stephen Gordon

University College Dublin, Ireland

One Health route to exploring virulence in the Mycobacterium tuberculosis complex (abstract)

1130 Hannah Painter

LSHTM, UK

Development of an ex vivo mycobacterial growth inhibition assay using murine lung cells for tuberculosis vaccine testing (abstract)

1150 Asst Prof Tufária Mussá

Eduardo Mondlane University, Mozambique

The fusion protein Ag85B-Acr-HBHA (FP1) elicits IFN-γ, IL-2 and TNF-α in conventional T cells of Tuberculosis contacts with latent infection over time (abstract)

1210 Lunch

1310 Session 3: Latest vaccine developments - Chair Prof Helen McShane, University of Oxford